| Editor's Note: Fierce PM Tracker will not publish on Thursday or Friday in observance of Independence Day. We'll be back in your inbox on Monday, July 7. |
|
Thursday, July 10, 2025 | 10am ET / 7am PT The transition from drug discovery to process development poses significant challenges. Join us for this deep dive into how adopting a collaborative approach between medicinal and process chemistry teams can help address key obstacles and accelerate progress from discovery to early clinical milestones. Register now. 
|
|
Today’s Big NewsJul 2, 2025 |
|
Thursday, July 22, 2025 | 10am ET / 7am PT Join us to take an exciting look at the forefront of REMS transformation. Learn how leading technology, integrated strategies and operational excellence are redefining what’s possible. Gain the insights you need to reduce complexity, enhance compliance and deliver more value across the REMS lifecycle. Register now. 
|
|
| By Darren Incorvaia A group of 53 biotech leaders are expressing their support for mifepristone in a letter to the Food and Drug Administration, urging the agency not to impose new restrictions on its use as an abortion medication and slamming a "fatally flawed" report cited as reasoning for the potential limitations. |
|
|
|
By Angus Liu After a delay, Regeneron’s BCMA-directed bispecific antibody Lynozyfic has won an FDA approval with a more convenient dosing regimen than competitor multiple myeloma offerings from Johnson & Johnson and Pfizer. |
By Conor Hale The pulsed field ablation developer collected $250 million to gear up for the commercial launch of its Globe system, planned for later this year. |
By Gabrielle Masson AN Venture Partners has closed its first fund, a $200 million vault for biotechs worldwide, with particular emphasis on bolstering Japan’s biopharma ecosystem. |
|
MedTech companies often launch groundbreaking devices, only to face slow adoption due to costly, time-intensive, and difficult-to-scale training. This whitepaper explores how Virtual Reality (VR) is changing that, helping teams engage physicians earlier, accelerate product adoption, and drive stronger commercial outcomes. Download now to learn more. 
|
|
By Nick Paul Taylor Boehringer Ingelheim has breathed life into an American Lung Association campaign, providing support for a push to educate people with bronchiectasis about how to better manage the disease. |
By Kevin Dunleavy AstraZeneca CEO Pascal Soriot is plotting a shift of the company’s primary stock listing from the London to the U.S., according to The Times. In the report, the British news outlet cites multiple unnamed sources, including one who added that Soriot has even discussed basing AZ’s business in the U.S. |
By James Waldron Whether it’s drug developers being pressured to wind down or investors accused of trying to “strip mine” a biopharma, shareholder meetings are increasingly becoming verbal battlegrounds for beleaguered biotechs. |
By Nick Paul Taylor A drug candidate Organon hailed as perhaps its “biggest potential opportunity” has flunked a phase 2 trial, prompting the company to end clinical development of the endometriosis prospect. |
By Angus Liu Chinese regulators have approved four new drugs developed by local biopharma companies, including a first-of-its-kind molecule in blood cancer. |
By Darren Incorvaia Storied Japanese pharma Shionogi is upping its arsenal in the fight against antibiotic resistance. The company is paying 5 million Swiss francs ($6.3 million) upfront for a preclinical antibiotic program from BioVersys on which the two companies will work to turn into clinical candidates. |
By Zoey Becker The latest project, a sterile product manufacturing site in Brnik, will bring Sandoz' total planned and ongoing investments in Slovenia to more than $1.1 billion by 2029. |
By Conor Hale The CE Mark covers adult and pediatric use spanning several endoscopic procedures, including in urology, gynecology and general laparoscopic surgery across the chest, abdomen and pelvis. |
Fierce podcasts Don’t miss an episode |
| In this episode of "Podnosis," we explore how mental healthcare can evolve into a more connected, whole-person model. |
|
|---|
|
|
|
In all the “what if” chatter and fatigue around AI, predictive sales intelligence is a key opportunity that can easily be implemented and scaled to make omnichannel strategies even more potent. Our whitepaper explores the value of this capability, what role it plays in evolving HCP engagement trends, how to implement, and what to look for when engaging new partners and solutions. Download now.
|
|
Whitepaper Presented by Blue Matter, strategic consultants in the life sciences Sponsored by Blue Matter Consulting |
Whitepaper We analyzed ~300 launches to identify the factors most correlated with commercial success & built a framework for peak go-to-market performance. Presented by Blue Matter, strategic consultants in the life sciences |
| Deadline Extended: July 2 |
|
| Sheraton Philadelphia Downtown |
|
|
| |
|
